A drug company said Friday that a medicine it sells to tamp down inflammation has helped prevent the need for breathing machines in hospitalized COVID-19 patients in the first large study that...
A drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day.
Excitement about treating the new coronavirus with malaria drugs is raising hopes, including with President Donald Trump. But the evidence that they may help is thin, and a run on the drugs is...
President Donald Trump focused attention on possible treatments for the new coronavirus on Thursday, citing potential use of a drug long used to treat malaria and some other approaches still in...
Former No. 1 and 2018 Australian Open champion Caroline Wozniacki will retire from professional tennis after competing in Melbourne next year.
TRENTON, N.J. (AP) — They were the drugs that were supposed to save the U.S. tens of billions of dollars.
Called "biosimilars," they are near-copies of complex and expensive biologic drugs...
SINGAPORE (AP) — Caroline Wozniacki was diagnosed with rheumatoid arthritis before the U.S. Open, the Danish tennis player revealed at the WTA Finals on Thursday.
She made the announcement after being eliminated from the year-end competition following a 5-7, 7-5, 6-3 loss to Elina Svitolina in her third round-robin match.
PORTLAND, Maine (AP) — A Maine woman who suffers from rheumatoid arthritis has told a senate committee that the high cost of treating the disease is an unfair burden on thousands of patients.
INDIANAPOLIS (AP) — Eli Lilly says it will resubmit its potential rheumatoid arthritis treatment to regulators several months faster than expected.
The drugmaker said Wednesday that it will give baricitinib back to the Food and Drug Administration for review by the end of January, and the agency will not require a new clinical study.
Federal regulators on Friday approved another alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders.
The U.S. Food and Drug Administration approved Renflexis, developed by Samsung Bioepis Co. of South Korea. Its U.S. partner, Merck & Co. of Kenilworth, New Jersey, will market Renflexis.
Federal regulators have approved an alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders.
The Food and Drug Administration said Friday that it approved Renflexis, developed by Samsung Bioepis Co. of South Korea. It will be marketed by its U.S. partner, Merck & Co. of Kenilworth, New Jersey.
Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker's second drug development setback since November.
The Food and Drug Administration said in a letter to the company that it needed more information about the drug's safety and the best doses, Lilly said Friday in a statement.
WASHINGTON (AP) — Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.
The Food and Drug Administration cleared a near-copy of the drug, dubbed Amjevita, developed by Amgen Inc. Regulators approved the drug for more than a half-dozen conditions listed on the original drug's label, including severe psoriasis and Crohn's diseases.
TRENTON, N.J. (AP) — A cheaper version of Johnson & Johnson's top-selling drug, the pricey rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled that a key patent on the drug is invalid.
WASHINGTON (AP) — The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases.
A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen's version of AbbVie's Humira, a biotech drug that raked in nearly $15 billion last year, according to IMS Health. While not binding,...